CIViC Evidence Items

37 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	MET	Overexpression	Predictive	Does Not Support	Sensitivity/Response	Stomach Carcinoma	Rilotumumab	Catenacci et al., 2017
D	MET	Amplification	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Gefitinib	Engelman et al., 2007
D	MET	Amplification	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Tanizaki et al., 2011
B	MET	Overexpression	Predictive	Supports	Resistance	Skin Melanoma	Vemurafenib	Hugo et al., 2015
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Crizotinib,Vemurafenib	Pietrantonio et al., 2016
C	MET	D1228V	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Cabozantinib	Bahcall et al., 2016
C	MET	D1228V	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Savolitinib	Bahcall et al., 2016
A	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Capmatinib	Wolf et al., 2020
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Gastric Adenocarcinoma	Onartuzumab	Catenacci et al., 2011
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Ou et al., 2011
D	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Crizotinib	Togashi et al., 2015
B	MET	Mutation	Predictive	Supports	Sensitivity/Response	Papillary Renal Cell Carcinoma	Foretinib	Choueiri et al., 2013
C	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	Paik et al., 2015
C	MET	Amplification AND MET Splice Site (c.3028G>A)	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Awad et al., 2016
C	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	Awad et al., 2016
C	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Capmatinib	Frampton et al., 2015
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Glioblastoma	Crizotinib	Chi et al., 2012
B	MET	Overexpression	Predictive	Does Not Support	Resistance	Skin Melanoma	Vemurafenib	Jubb et al., 2013
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	Le et al., 2015
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Cancer	Crizotinib	Palma et al., 2014
C	MET	Amplification AND NOT KRAS Mutation	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab/Irinotecan Regimen,Panitumumab	Bardelli et al., 2013
D	MET	Amplification AND NOT KRAS Mutation	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Crizotinib,Cetuximab	Bardelli et al., 2013
D	MET	Overexpression	Predictive	Supports	Resistance	Uveal Melanoma	Trametinib,Selumetinib	Cheng et al., 2015
B	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Tepotinib	Enriqueta Felip, 2018, ASCO Annual Meeting, Abstract 9016
C	MET	R1004G	Predictive	Supports	Sensitivity/Response	Head And Neck Cancer	Crizotinib	Chu et al., 2019
C	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Histiocytic And Dendritic Cell Cancer	Crizotinib	Frampton et al., 2015
D	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Capmatinib	Frampton et al., 2015
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	Zhang et al., 2016
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Lung Squamous Cell Carcinoma	Crizotinib	Schwab et al., 2014
C	MET	Amplification	Predictive	Supports	Resistance	Lung Adenocarcinoma	Erlotinib,Gefitinib	Yu et al., 2013
C	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	Shea et al., 2016
C	MET	D1228N	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	Heist et al., 2016
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Caparica et al., 2017
C	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Mahjoubi et al., 2016
D	MET	Overexpression	Predictive	Supports	Sensitivity/Response	Uveal Melanoma	Crizotinib	Surriga et al., 2013
C	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	Jenkins et al., 2015
B	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Alexander E. Drilon, 2016, ASCO Annual Meeting, Abstract 108